These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24630695)

  • 1. Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.
    Chatzopoulou M; Patsilinakos A; Vallianatou T; Prnova MS; Zakelj S; Ragno R; Stefek M; Kristl A; Tsantili-Kakoulidou A; Demopoulos VJ
    Bioorg Med Chem; 2014 Apr; 22(7):2194-207. PubMed ID: 24630695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relations on [1-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone. The effect of methoxy substitution on aldose reductase inhibitory activity and selectivity.
    Chatzopoulou M; Mamadou E; Juskova M; Koukoulitsa C; Nicolaou I; Stefek M; Demopoulos VJ
    Bioorg Med Chem; 2011 Feb; 19(4):1426-33. PubMed ID: 21288726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
    Papastavrou N; Chatzopoulou M; Ballekova J; Cappiello M; Moschini R; Balestri F; Patsilinakos A; Ragno R; Stefek M; Nicolaou I
    Eur J Med Chem; 2017 Apr; 130():328-335. PubMed ID: 28259841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative structure-activity relationship of spirosuccinimide type aldose reductase inhibitors diminishing sorbitol accumulation in vivo.
    Ko K; Won H; Won Y
    Bioorg Med Chem; 2006 May; 14(9):3090-7. PubMed ID: 16412651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
    Stefek M; Tsantili-Kakoulidou A; Milackova I; Juskova M; Snirc V; Triantos N
    Bioorg Med Chem; 2011 Dec; 19(23):7181-5. PubMed ID: 22037047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship studies of quinoxaline derivatives as aldose reductase inhibitors.
    Wu B; Yang Y; Qin X; Zhang S; Jing C; Zhu C; Ma B
    ChemMedChem; 2013 Dec; 8(12):1913-7. PubMed ID: 24115741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.
    Majekova M; Ballekova J; Prnova M; Stefek M
    Bioorg Med Chem; 2017 Dec; 25(24):6353-6360. PubMed ID: 29074349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.
    Papastavrou N; Chatzopoulou M; Pegklidou K; Nicolaou I
    Bioorg Med Chem; 2013 Sep; 21(17):4951-7. PubMed ID: 23891165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [1-(3,5-difluoro-4-hydroxyphenyl)-1H-pyrrol-3-yl]phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor.
    Nicolaou I; Zika C; Demopoulos VJ
    J Med Chem; 2004 May; 47(10):2706-9. PubMed ID: 15115413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics and molecular docking studies of an anti-diabetic complication inhibitor fucosterol from edible brown algae Eisenia bicyclis and Ecklonia stolonifera.
    Jung HA; Islam MN; Lee CM; Oh SH; Lee S; Jung JH; Choi JS
    Chem Biol Interact; 2013 Oct; 206(1):55-62. PubMed ID: 23994501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides.
    Nicolaou I; Demopoulos VJ
    J Med Chem; 2003 Jan; 46(3):417-26. PubMed ID: 12540241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.
    Maccari R; Vitale RM; Ottanà R; Rocchiccioli M; Marrazzo A; Cardile V; Graziano AC; Amodeo P; Mura U; Del Corso A
    Eur J Med Chem; 2014 Jun; 81():1-14. PubMed ID: 24819954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.
    Pegklidou K; Koukoulitsa C; Nicolaou I; Demopoulos VJ
    Bioorg Med Chem; 2010 Mar; 18(6):2107-2114. PubMed ID: 20189816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxymethylated pyridoindole antioxidants as aldose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling.
    Stefek M; Snirc V; Djoubissie PO; Majekova M; Demopoulos V; Rackova L; Bezakova Z; Karasu C; Carbone V; El-Kabbani O
    Bioorg Med Chem; 2008 May; 16(9):4908-20. PubMed ID: 18395454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Sibley EO; McCann EE; Combs KJ; Flam B; Sawicki DR; Sabetta A; Carrington A; Sredy J; Howard E; Mitschler A; Podjarny AD
    Bioorg Med Chem; 2004 Nov; 12(21):5661-75. PubMed ID: 15465344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
    Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
    Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications.
    Saraswat M; Muthenna P; Suryanarayana P; Petrash JM; Reddy GB
    Asia Pac J Clin Nutr; 2008; 17(4):558-65. PubMed ID: 19114390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel synthesis of nitro-quinoxalinone derivatives as aldose reductase inhibitors.
    Hussain S; Parveen S; Qin X; Hao X; Zhang S; Chen X; Zhu C; Ma B
    Bioorg Med Chem Lett; 2014 May; 24(9):2086-9. PubMed ID: 24726808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Acetyl-5-phenyl-1H-pyrrol-3-ylacetate: An aldose reductase inhibitor for the treatment of diabetic nephropathy.
    Xiu ZM; Wang LP; Fu J; Xu J; Liu L
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4482-4487. PubMed ID: 28802633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.
    Stefek M; Soltesova Prnova M; Majekova M; Rechlin C; Heine A; Klebe G
    J Med Chem; 2015 Mar; 58(6):2649-57. PubMed ID: 25695864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.